secwatch.observer — SEC 8-K summary
======================================

Issuer:     ZEVRA THERAPEUTICS, INC. (ZVRA)
CIK:        0001434647
Form:       8-K
Filed at:   2024-08-09T23:59:59+00:00
Accession:  0001193125-24-197943
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Zevra Therapeutics prices $60M common stock offering at $6.50/share; net proceeds ~$56.1M
--------------------------------------------------------------------------------

- 9,230,770 shares sold at $6.50; underwriters have 30-day option for 1,384,615 additional shares.
- Net proceeds estimated at $56.1M after underwriting discounts and offering expenses.
- Proceeds to fund pre-commercial launch of arimoclomol, OLPRUVA support, and development of celiprolol and KP1077.
- Company believes net proceeds plus existing cash will fund operations through Q1 2026; closing expected Aug 12, 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1434647/000119312524197943/0001193125-24-197943-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1434647/000119312524197943/d723355d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-197943

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer